CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 50 enrolled
Drug / intervention
Nicotine (2 mg) +1 moredrug
Likely dose
Nicotine (2 mg)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01536704
NCT01536704Phase 1Completed

A Single Dose Bioequivalence Study of 2 Different Doses of Mini Cherry Nicotine Lozenges

GlaxoSmithKline·interventional·Posted Feb 22, 2012·Updated Apr 26, 2013

In Brief

A Phase 1 clinical trial evaluating Nicotine (2 mg) and Nicotine (4 mg) for Smoking Cessation. Completed, enrolled 50 participants across 1 site.

Detailed Summary

To compare the bio equivalence of new nicotine lozenge formulation with the reference nicotine lozenge so as to deliver the same nicotine blood profile.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 22, 2012
Enrollment StartJul 1, 2011
Primary CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 14.4 years ago

Interventions

Nicotine (2 mg)drug

2 mg nicotine lozenge in two formulations

Nicotine (4 mg)drug

4 mg nicotine lozenge in two formulations